According to data collected fromvarious sources and compiled by Coherent Market Insights, Europe have thehighest annual rate of incidence worldwide, followed by North America and thelowest in Asia and Middle East.
However, North America holds thelargest share in the global UlcerativeColitis Market due to continuous improvements in drugs, increased uptake ofmedicines, awareness about treatment and increasing clinical research. APACregion will show high growth in ulcerative colitis market during forecast years(2017-2024), due to raising awareness about the treatment, changing lifestylewill cause to increase prevalence and incidence rate, entry of new drugs in themarket also some companies losing their patent of ulcerative drugs in comingyears, like Humira (adalimumab) lost its patent in 2016 and Remicade will loseits patent in 2018. Also, some drugs companies have launched their biosimilardrugs in ulcerative colitis industry. For example, in 2016, India-based TorrentPharmaceuticals launched a biosimilar drug under the brand name Adfra tocompete Humira. Humira is a trade name for adalimumab medication owned byAbbVie Inc.
Some major companies playingleading role in ulcerative colitis market are AbbVie Inc., Hospira, CelltrionHealthcare, Johnson and Johnson, F. Hoffmann-La Roche AG, Warner Chilcott,Janssen Pharmaceuticals Inc. and Takeda Pharmaceuticals Company Ltd.
Ulcerative colitis is the mostcommon type of inflammatory bowel disease that affects the colon (lining of thelarge intestine) and rectum. The inflammation produces tiny sores calledulcers. These disease can affect people of any age, though prevalence isespecially high among people under 30 years of age. The major symptoms of thisdisease are diarrhea, belly pain/cramps, bleeding from the rectum, also otherindications are sudden and unexplained weight loss, loss of appetite, jointpain, eye disease, thickening of the intestinal wall, blood infection (sepsis),kidney stones and liver disease. The diagnosis of this disease can be carriedout by physical examination using tests such as colonoscopy, endoscopy, biopsy,CT scan and blood test.
* The sample copy includes: Report Summary, Table ofContents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/238
If ulcerative colitis persistsfor over 8 years or longer, it may lead to colon cancer. The people having mildsymptoms of this disease can be cured by over the counter drugs such as Imodiumtherapy. However, transcription medicine such as steroid medicines and aminosalicylates are widely used to treat the condition. In severe cases, the patientmay need to undergo surgery to remove the colon, which also helps prevent coloncancer.
Also, some genetically engineereddrugs also used to treat ulcerative colitis. These drugs are made up of certainliving organisms that help suppress the inflammation, by targeting theinflammatory proteins such as cytokines. Some genetically engineered drugsapproved by the U.S. FDA for treatment of the condition are Adalimumab(Humira), Golimumab (Simponi), Infliximab (Remicade) and Vedolizumab (Entyvio).
These genetically engineereddrugs may show some side effects such as fever, headache, hives, low bloodpressure, breathing difficulties, back pain, and stomach pain. Also, thesedrugs may affect the immunity power of body to fight infection.
The exact cause for ulcerativecolitis is unknown, though possible reasons are may be genetic factors,environmental changes, or weakened immune system. The ulcerative colitis can beprevented by simple healthy habits such as eating small meals throughout theday, staying well hydrated throughout the day, avoiding fatty foods, and limitingintake of high-fiber food.
According to data released by theCenters for Disease Control and Prevention (CDC), there are around 2.2 to 14.3cases found per 100,000 population per year. Also, according to a studyconducted in 2014 by Crohn’s & Colitis Foundation of America (CCFA),907,000 people suffered from ulcerative colitis in the U.S. (data based on theresearch conducted in between 2011-2014 by CCFA)
High prevalence in developedregions and increasing incidence rate in emerging economies will play majorrole in driving growth of the ulcerative colitis market
According to the study of CCFA,industrialized countries have highest incidence rate for ulcerative colitis.This disease is most prevalent in urban areas than in rural areas, also it canaffect to any age group of people but most cases diagnosed are of the age inbetween 15 to 35. According the stats of World Gastroenterology Organization(WGO), there is rising incidence rate in emerging economies such as India. Dueto changing diet and lifestyle pattern, the emerging economies will show highgrowth rate in incidence rate of ulcerative colitis in the near future.
Browse ResearchReport: https://www.coherentmarketinsights.com/ongoing-insight/ulcerative-colitis-market-238
Some leading drugs are used toreduce inflammation and swelling and to cure ulcerative colitis are includeSulfasalazine (Azulfidine), Mesalamine (Asacol and Lialda), Balsalazide(Colazal), and Olsalazine (Dipentum), Inflectra, Remsima, Adalimumab (Humira),and Infliximab (Remicade).
Key Developments
Key players in the market arefocused on various growth strategies such research and development of novelproducts, in order to enhance their product portfolio. For instance, in October2018, Pfizer, Inc.’s Xeljanz, an oral Janus kinase inhibitor showed effectivenessand safety in the treatment of ulcerative colitis in a 24-month open labelextension study.
Major companies in the market areinvolved in various business strategies such research and development of novelproducts, in order to enhance their product portfolio. For instance, in March2019, The Janssen Pharmaceutical Companies of Johnson & Johnson announcedthe Phase III data UNFI study data for Stelara, a subcutaneous maintenancetherapy, which showed positive results as maintenance therapy in adultssuffering from moderate to severe ulcerative colitis.
Major companies in the market areinvolved in various growth strategies such research and development of novelproducts, in order to enhance their market presence. For instance, in August2019, Takeda Pharmaceutical Company Limited, submitted new drug application(NDA) to Ministry of Health, Labour and Welfare in Japan for subcutaneousformulation of vedolizumab, which will be used as maintenance therapy in adultswith moderate to severe ulcerative colitis.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/238
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
